Notice Number: NOT-MH-13-007
Key Dates
Release Date: November 28, 2012
Estimated Publication Date of Announcement: January 22, 2013
First Estimated Application Due Date: February 22, 2013
Earliest Estimated Award Date: December 2013
Earliest Estimated Start Date: December 2013
PAR-11-206
Issued by
National Institute of Mental Health (NIMH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Drug Abuse (NIDA)
Purpose
The purpose of this Notice is to inform potential applicants that the National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute on Drug Abuse (NIDA) intend to reissue PAR-11-206 “National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (UM1)”, which will expire on February 23, 2013.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
This FOA will use NIH’s new Application Submission System & Interface for Submission Tracking (ASSIST) for the electronic preparation and submission of multi-project applications through Grants.gov to NIH. Applications to this FOA must be submitted electronically; paper applications will not be accepted. ASSIST replaces the Grants.gov downloadable forms currently used with most NIH opportunities and provides many features to enable electronic multi-component application submission and improve data quality, including: pre-population of organization and PD/PI data, pre-submission validation of many agency business rules and the generation of data summaries in the application image used for review.
The FOA, which will use the Multi-Component Research Project Cooperative Agreements (UM1) award mechanism, is expected to be published in December 2012 or January 2013, with an expected receipt date in February 2013. Details of the planned FOA are provided below.
Research Initiative Details
The purpose of this planned initiative is to create multidisciplinary research groups or partnerships for the discovery of pharmacological agents to treat and to study mental illness, drug or alcohol addiction. The objectives of this program are to: accelerate innovative drug discovery; develop pharmacologic tools for basic and clinical research on mental disorders, or drug or alcohol addiction; develop and validate models for evaluating novel therapeutics for mental disorders; and support early phase human clinical testing to rapidly assess the safety and efficacy of promising drug candidates and new indications for IND-ready agents for the treatment of mental disorders or alcohol addiction.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Inquiries
Inquiries regarding this Notice may be directed to:
Linda Brady, Ph.D.National Institute of Mental Health
Telephone: (301) 443-3563
Email: [email protected]
and Human Services (HHS)
